Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Divestments Dividends Paid - Common Dividends Paid - Common Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

BridgeBio Pharma (BBIO) Asset Writedowns and Impairment (2021 - 2022)

BridgeBio Pharma (BBIO) has disclosed Asset Writedowns and Impairment for 2 consecutive years, with $67000.0 as the latest value for Q3 2022.

Quarterly Asset Writedowns and Impairment changed N/A to $67000.0 in Q3 2022 from the year-ago period, while the trailing twelve-month figure was $67000.0 through Jun 2023, down 99.28% year-over-year, with the annual reading at $271000.0 for FY2024, N/A changed from the prior year.
Asset Writedowns and Impairment hit $67000.0 in Q3 2022 for BridgeBio Pharma, down from $12.7 million in the prior quarter.
In the past five years, Asset Writedowns and Impairment ranged from a high of $12.7 million in Q1 2022 to a low of -$3.3 million in Q4 2021.